Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 5, 1998, Pages 471-477

  Talesnik, Eduardo ^a   Vial, Pablo A ^a   Labarca, Jaime ^a   Méndez, Cecilia ^a   Soza, Ximena ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

AIDS; Antibody response; Chile; HIV; Pneumococcal capsular polysaccharides; Tetanus toxoid

Indexed keywords

PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CHILE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LYMPHOCYTE PROLIFERATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MEMORY CELL; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION;

HUMAN IMMUNODEFICIENCY VIRUS; PNEUMOCOCCUS; RNA VIRUSES; STREPTOCOCCUS PNEUMONIAE;

EID: 0032534849     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199812150-00005     Document Type: Article

References (38)

1. Fauci AS. The human immunodeficiency virus: infectivity and mechanism of pathogenesis. Science 1988;239:617-23.
2. Gottlieb MS, Groopman JE, Weinstein WM, Fahey JL, Detels R. The acquired immunodeficiency syndrome. Ann Intern Med 1983; 99:208-20.
3. Fauci AS, Macher AM, Longo DL, et al. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med 1984;100:92-106.
4. Polsky B, Gold JWM, Whimbey E, et al. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Inrern Med 1986;104:38-41.
5. Witt DJ, Craven DE, McCabe WR. Bacterial infections in adult patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Am J Med 1987;82:900-6.
6. Simberkoff MS, El Sadr WE, Schiffman G, Rahal JJ. Streptococcus pneumoniae infections and bacteremia in patients with acquired immunodeficiency syndrome, with report of pneumococcal vaccine failure. Am Rev Respir Dis 1984;130:1174-6.
7. Selwyn PA, Feingold AR, Hartel DE, Schoenbaum EE, Aldermann MH, Klein RS. Increased risk of bacteremia pneumonia in HIV-infected intravenous drug users without acquired immunodeficiency syndrome. AIDS 1988;2:267-72.
8. Huang L-K, Ruben FL, Rinaldo C, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA 1987;257:2047-50.
9. Janoff E, Breiman R, Daley CL, Hopewell P. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992;117:314-24.
10. Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 1986;63:127-34.
11. Stevens R, Dichek D, Keld B, Heiner D. IgG1 is the predominant subclass of in vivo and in vitro produced anti-tetanus toxoid antibodies and also serves as the membrane IgG molecule for delivering inhibitory signals to anti-tetanus toxoid antibody producing B cells. J Clin Immunol 1983;3:65-9.
12. Opravil M, Fierz W, Matter L, Blaser J, Luthy R. Poor antibody response after tetanus and pneumococcal vaccination in immuno-compromised, HIV-infected patients. Clin Exp Immunol 1991;84: 185-9.
13. Glaser JB, Volpe S, Aguirre A, Simpkins H, Schiffman G. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J Infect Dis 1991;164: 761-4.
14. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-19.
15. Killingsworth LM, Savory J. Automated immunochemical procedures for measurement of immunoglobulin in human serum. Clin Chem 1971;17:936-40.
16. Jefferis R, Reimer CB, Skvaril J, et al. Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of an IUIS/WHO collaborative study. Immunol Lett 1985;10:223-52.
17. Nicholson JKA. Use of flow cytometry in the evaluation and diagnosis of primary and secondary immunodeficiency diseases. Arch Pathol Lab Med 1989;113:598-605.
18. Landay AL, Ohlsson-Wilhelm B, Giorgi JV. Application of flow cytometry for the study of HIV infection. AIDS 1990;4:479-97.
19. Janoff EN, Douglas JM, Gabriel M, et al. Class specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J Infect Dis 1988;158:983-90.
20. Rubin RL, Tang F-L, Lucas AH, Spiegelberg HL, Tan EN. IgG subclasses of antitetanus toxoid antibodies in adults and newborn normal subjects and in patients with systemic lupus erythematosus, Sjögren's syndrome and drug induced autoimmunity. J Immunol 1986;137:2522-7.
21. Godfrey K. Comparing the means of several groups. In Bailar III JC, Mosteller F. Medical uses of statistics, 2nd edition. Boston, MA: NEJM Books, 1992:233-57.
22. Mancini G, Carbonara A. Immunochemical quantitation of antigens by radial immunodiffusion. Immunochemistry 1965;2:235-54.
23. Schiebel Y. The uses and results of active tetanus immunization. Bull WHO 1955;13:381.
24. Aucouturier P, Couderc LJ, Gouet DE, et al. Serum immunoglobulin G subclass dysbalances in the lymphadenopathy syndrome and acquired immune deficiency syndrome. Clin Exp Immunol 1986;63:234-40
25. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983;309:453-8.
26. Teeuwsen VJ, Logtenberg T, Siebelink KH, et al. Analysis of the antigen and mitogen-induced differentiation of B lymphocytes from asymptomatic human immunodeficiency virus-seropositive male homosexuals. J Immunol 1987;139:2929-35.
27. Janoff EN, Hardy WD, Smith PD, Wahl SH. Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. J Infect Dis 1991;147:2130-5.
28. Maria VA, Pinto LA, Victorino RM. Inhibition of lymphocyte proliferation induced in vitro by microbial antigens in HIV-infected subjects. J Med Virol 1991;35:241-5.
29. Nelson KE, Clements ML, Miotti P, Cohn S, Polk F. The influence of immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988;109:383-8.
30. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.
31. Christenson B, Bottiger M. Epidemiology and immunity to tetanus in Sweden. Scand J Infect Dis 1987;19:429-35.
32. Chudwin DS, Astrip SG, Schiffman G. Immunoglobulin G class and subclass antibodies to pneumococcal capsular polysaccharides. Clin Immmunol Immunopathol 1987;44:114-21.
33. Vandenbruaene C, Colebunders R, Mascart-Lemone F, et al. Equal IgG antibody response to pneumococcal vaccine in all stages of human immunodeficiency virus disease. J Infect Dis 1995;172: 551-3.
34. + lymphocytes. AIDS 1994;8:469-76.
35. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992;165:553-6.
36. Rodriguez-Barradas MC, Groover JC, Lacke C, et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus infected subject: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J Infect Dis 1996;173:1347-53.
37. Baker P. Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes. Infect Immunol 1990;58:3465-8.
38. Mondd JJ, Vos QUE, Lees A, Snapper CM. T-cell independent antigens. Curr Opin Immunol 1995;7:349-54.